Each mL of reconstituted solution contains 20 mg ziprasidone. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group.Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. For current full prescribing information, please visit www.pfizer.comThe easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Dosage adjustments, if indicated, should generally occur at intervals of not less than 2 days, as steady-state is achieved within 1 to 3 days. Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Geodon during pregnancy Advise breastfeeding women using Geodon to monitor infants for excess sedation, irritability, poor feeding, and extrapyramidal symptoms (tremors, and abnormal muscle movements) and to seek medical care if they notice these signs Advise females of reproductive potential that Geodon may impair fertility due to an increase in serum prolactin levels. Note that for the flexible dose studies in both schizophrenia and bipolar disorder, each subject is categorized as having received either low (20–40 mg BID) or high (60–80 mg BID) dose based on the subject's modal daily dose.

In the second phase of the trial, ECGs were obtained at the time of maximum plasma concentration while the drug was co-administered with an inhibitor of the CYP4503A4 metabolism of the drug.In the first phase of the study, the mean change in QTc from baseline was calculated for each drug, using a sample-based correction that removes the effect of heart rate on the QT interval. When deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone’s greater capacity to prolong the QT/QTc interval compared to several other antipsychotic drugs [see Warnings and Precautions (5.3) ] .

NMS is a rare but serious side effect that could be fatal. The possibility of obtundation, seizure, or dystonic reaction of the head and neck following overdose may create a risk of aspiration with induced emesis.Cardiovascular monitoring should commence immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmias. All trials were in adult inpatients, most of whom met DSM III-R criteria for schizophrenia. CONCLUSION: Intramuscular ziprasidone in this series of elderly patients suggests acceptable safety and efficacy in the management of acute psychotic agitation among elderly patients with schizophrenia. It is essential to periodically monitor serum electrolytes in patients for whom diuretic therapy is introduced during ziprasidone treatment. In long-term (at least 1 year), placebo-controlled, flexible-dose studies in schizophrenia, the mean change from baseline in random total cholesterol for ziprasidone 20–40 mg BID was +2.5 mg/dL (N=14); for ziprasidone 60–80 mg BID was -19.7 mg/dL (N=10); and for placebo was -28.0 mg/dL (N=9).Weight gain has been observed with atypical antipsychotic use. A reaction was considered treatment emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation.The following findings are based on the short-term placebo-controlled premarketing trials for schizophrenia (a pool of two 6-week, and two 4-week fixed-dose trials) and bipolar mania (a pool of two 3-week flexible-dose trials) in which ziprasidone was administered in doses ranging from 10 to 200 mg/day.The following adverse reactions were the most commonly observed adverse reactions associated with the use of ziprasidone (incidence of 5% or greater) and not observed at an equivalent incidence among placebo-treated patients (ziprasidone incidence at least twice that for placebo):Approximately 4.1% (29/702) of ziprasidone-treated patients in short-term, placebo-controlled studies discontinued treatment due to an adverse reaction, compared with about 2.2% (6/273) on placebo. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.Geodon Capsules are differentiated by capsule color/size and are imprinted in black ink with "Pfizer and ZDX [dosage strength]" or "Pfizer" and a unique number. Your doctor can best discuss the duration of treatment you need based on your symptoms and illness.The following are trademarks of NAMI: NAMI, NAMI Basics, NAMI Connection, NAMI Ending the Silence, NAMI FaithNet, NAMI Family & Friends, NAMI Family Support Group, NAMI Family-to-Family, NAMI Grading the States, NAMI Hearts & Minds, NAMI Homefront, NAMI HelpLine, NAMI In Our Own Voice, NAMI On Campus, NAMI Parents & Teachers as Allies, NAMI Peer-to-Peer, NAMI Provider, NAMI Smarts for Advocacy, Act4MentalHealth, Vote4MentalHealth, NAMIWalks and National Alliance on Mental Illness.

This possibility needs to be considered in deciding among alternative drug products Certain circumstances may increase the risk of the occurrence of torsade de pointes and/or sudden death in association with the use of drugs that prolong the QTc interval, including (1) bradycardia; (2) hypokalemia or hypomagnesemia; (3) concomitant use of other drugs that prolong the QTc interval; and (4) presence of congenital prolongation of the QT interval.It is recommended that patients being considered for ziprasidone treatment who are at risk for significant electrolyte disturbances, hypokalemia in particular, have baseline serum potassium and magnesium measurements.